Content about Hodgkin's lymphoma

July 22, 2013

The philanthropic division of supermarket chain Stater Bros. has raised more than a quarter-million dollars for blood cancers.

SAN BERNARDINO, Calif. — The philanthropic division of supermarket chain Stater Bros. has raised more than a quarter-million dollars for blood cancers.

Stater Bros. Charities and The Leukemia & Lymphoma Society said their "Light the Night" fundraising campaign raised $331,462. The campaign focuses on leukemia, Hodgkin and non-Hodgkin lymphoma, myeloma and myelodysplastic syndromes.

The company sold paper balloons at its 166 stores last month for $1 each. The campaign is in its sixth year and has raised more than $1.8 million in total.

April 26, 2013

More than 200 drugs for blood cancers are under development, according to a new report by a drug industry trade group.

WASHINGTON — More than 200 drugs for blood cancers are under development, according to a new report by a drug industry trade group.

The Pharmaceutical Research and Manufacturers of America said 241 medicines were in clinical development or under review by the Food and Drug Administration, including 98 for lymphoma, 97 for leukemia, 52 for multiple myeloma and 24 for malignancies of the bone marrow, blood and lymph nodes.

December 27, 2012

A national drug shortage has been linked to a higher rate of relapse among children, teenagers and young adults with Hodgkin lymphoma enrolled in a national clinical trial, according to research led by St. Jude Children's Hospital.

MEMPHIS  — A national drug shortage has been linked to a higher rate of relapse among children, teenagers and young adults with Hodgkin lymphoma enrolled in a national clinical trial, according to research led by St. Jude Children's Hospital.

The study found the estimated two-year cancer-free survival for patients enrolled in the study fell from 88% to 75% after the drug cyclophosphamide was substituted for mechlorethamine for treatment of patients with intermeidiate- or high-risk Hodgkin lymphoma. The study was launched before the drug shortages began.

May 9, 2012

Seattle Genetics and Takeda's cancer drug subsidiary have started a late-stage clinical trial for a lymphoma drug, the companies said Wednesday.

BOTHELL, Wash. — Seattle Genetics and Takeda's cancer drug subsidiary have started a late-stage clinical trial for a lymphoma drug, the companies said Wednesday.

Seattle Genetics and Millennium announced the start of a phase-3 trial of Adcetris (brentuximab vedotin) in patients relapsed cutaneous T-cell lymphoma that expresses the CD30 cell membrane protein. The study will enroll more than 120 patients who will be divided into two groups, one of which will receive Adcetris and another that will receive methotrexate or bexarotene.

March 6, 2012

Takeda Pharmaceutical's cancer drug unit has started a late-stage clinical trial of a drug for treating a rare form of lymphoma, the company said.

CAMBRIDGE, Mass. — Takeda Pharmaceutical's cancer drug unit has started a late-stage clinical trial of a drug for treating a rare form of lymphoma, the company said.

The unit, Millennium, announced the start of a phase-3 trial to evaluate MLN8237 in patients with relapsed or refractory peripheral T-cell lymphoma, an aggressive non-Hodgkin's lymphoma.

August 19, 2011

The Food and Drug Administration has approved a new biotech drug for treating two types of lymphoma, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new biotech drug for treating two types of lymphoma, the agency said Friday.

September 8, 2010

NEW YORK British drug maker GlaxoSmithKline and biotech company Genmab have started a late-stage trial...

NEW YORK British drug maker GlaxoSmithKline and biotech company Genmab have started a late-stage trial of a biotech drug for treating cancer, the two companies said.

 

June 15, 2010

Stater Bros. is partnering with The Leukemia & Lymphoma Society for three weeks in June...

April 19, 2010

In the first study of vitamin K and non-Hodgkin's lymphoma risk, researchers at the Mayo...

WASHINGTON In the first study of vitamin K and non-Hodgkin's lymphoma risk, researchers at the Mayo Clinic campus in Minnesota have found that people who have higher intakes of vitamin K from their diet have a lower risk of developing non-Hodgkin's lymphoma.

 

March 22, 2010

A Food and Drug Administration advisory committee declined to recommend approval for a cancer drug...